OMass Therapeutics raised $310 million in Series C financing co-led by Bain Capital Life Sciences, Forbion, and Novo Holdings. The U.K. biotech will use the capital to advance lead asset OMS1620, an MC2 receptor antagonist, into Phase 2 trials for congenital adrenal hyperplasia. The financing positions OMass to compete with Neurocrine Biosciences' Crenessity—which generated $301.2 million in 2025—and Vertex Pharmaceuticals' atumelnant.
OMass Therapeutics raises Series C funding
- ▪OMass Therapeutics announced on October 15, 2026 that it closed a $310 million Series C financing round to advance its rare endocrine disorder pipeline
- ▪Investors participating in OMass Therapeutics' Series C round included Janus Henderson Investors, SV Health Investors, Jefferson Life Sciences, Syncona, Oxford Science Enterprises, GV, Northpond Ventures, Sanofi Ventures, and the University of Oxford
- ▪Bain Capital Life Sciences, Forbion, and Novo Holdings co-led the $310 million Series C funding round for OMass Therapeutics
Development of lead candidate OMS1620
- ▪OMass Therapeutics' lead drug candidate, OMS1620, is a small molecule designed to block the melanocortin-2 (MC2) receptor in the adrenal glands
- ▪OMass Therapeutics will use its Series C funding to advance OMS1620 through Phase 2 clinical trials for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome
- ▪OMS1620 is designed to maintain prolonged target binding to reduce adrenal hormone overproduction in patients taking glucocorticoids for congenital adrenal hyperplasia
OMass Therapeutics expands broader pipeline
- ▪OMass Therapeutics is developing a potential first-in-class SLC15A4 inhibitor for lupus and other immune conditions linked to interferon overproduction and pathogenic B-cell activation
- ▪OMass Therapeutics is allocating part of its $310 million Series C capital to support its broader pipeline of earlier-stage drug assets
Congenital adrenal hyperplasia overview and treatment
- ▪Standard treatment for congenital adrenal hyperplasia relies on high doses of synthetic glucocorticoids, which cause severe side effects and risk life-threatening adrenal crisis if cortisol levels drop
- ▪Congenital adrenal hyperplasia is an inherited endocrine disorder where an enzyme deficiency in the adrenal glands leads to severe hormonal imbalances, low sodium levels, and dehydration
Neurocrine Biosciences markets Crenessity
- ▪Neurocrine Biosciences markets Crenessity, an oral CRFR1 inhibitor approved by the FDA in 2024 as the primary targeted drug for congenital adrenal hyperplasia
- ▪Neurocrine Biosciences reported $301.2 million in Crenessity revenue for full-year 2025
Vertex Pharmaceuticals develops atumelnant
- ▪Vertex Pharmaceuticals is developing atumelnant, an oral small molecule ACTH inhibitor, to treat congenital adrenal hyperplasia
- ▪Vertex Pharmaceuticals acquired the clinical drug candidate atumelnant through its $10 billion acquisition of Crinetics Pharmaceuticals
Story comments
Loading comments…